NZ335994A - Sevoflurane compositions and methods for inhibiting their degradation in the presence of a lewis acid - Google Patents

Sevoflurane compositions and methods for inhibiting their degradation in the presence of a lewis acid

Info

Publication number
NZ335994A
NZ335994A NZ335994A NZ33599498A NZ335994A NZ 335994 A NZ335994 A NZ 335994A NZ 335994 A NZ335994 A NZ 335994A NZ 33599498 A NZ33599498 A NZ 33599498A NZ 335994 A NZ335994 A NZ 335994A
Authority
NZ
New Zealand
Prior art keywords
lewis acid
sevoflurane
inhibiting
degradation
compositions
Prior art date
Application number
NZ335994A
Other languages
English (en)
Inventor
Christopher Bieniarz
Steve H Chang
Keith R Cromack
Shuyen Huang
Toshikazu Kawai
Manami Kobayashi
David Loffredo
Rajagopalan Raghavan
Earl R Speicher
Honorate A Stelmach
Original Assignee
Central Glass Co Ltd
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25148366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ335994(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Central Glass Co Ltd, Abbott Lab filed Critical Central Glass Co Ltd
Publication of NZ335994A publication Critical patent/NZ335994A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Catalysts (AREA)
  • Steroid Compounds (AREA)
NZ335994A 1997-01-27 1998-01-23 Sevoflurane compositions and methods for inhibiting their degradation in the presence of a lewis acid NZ335994A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/789,679 US5990176A (en) 1997-01-27 1997-01-27 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
PCT/US1998/001376 WO1998032430A1 (en) 1997-01-27 1998-01-23 Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid

Publications (1)

Publication Number Publication Date
NZ335994A true NZ335994A (en) 2000-08-25

Family

ID=25148366

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ335994A NZ335994A (en) 1997-01-27 1998-01-23 Sevoflurane compositions and methods for inhibiting their degradation in the presence of a lewis acid

Country Status (27)

Country Link
US (6) US5990176A (https=)
EP (2) EP1114641B1 (https=)
JP (5) JP3183520B2 (https=)
KR (1) KR100368672B1 (https=)
CN (3) CN1899271A (https=)
AR (2) AR011090A1 (https=)
AT (2) ATE320798T1 (https=)
AU (1) AU726733B2 (https=)
BG (2) BG65414B1 (https=)
BR (1) BR9806996A (https=)
CA (2) CA2278133C (https=)
CO (1) CO4920220A1 (https=)
CZ (1) CZ297092B6 (https=)
DE (2) DE69833884T2 (https=)
DK (2) DK1114641T3 (https=)
ES (2) ES2170474T3 (https=)
GR (1) GR3036190T3 (https=)
HU (1) HUP0002101A3 (https=)
IL (1) IL130150A (https=)
NO (1) NO993606L (https=)
NZ (1) NZ335994A (https=)
PL (1) PL334477A1 (https=)
PT (2) PT967975E (https=)
SK (1) SK284243B6 (https=)
TR (1) TR199901579T2 (https=)
WO (1) WO1998032430A1 (https=)
ZA (1) ZA98418B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990176A (en) * 1997-01-27 1999-11-23 Abbott Laboratories Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
US6162443A (en) * 1998-01-09 2000-12-19 Abbott Laboratories Container for an inhalation anesthetic
US6074668A (en) * 1998-01-09 2000-06-13 Abbott Laboratories Container for an inhalation anesthetic
US20030200963A1 (en) * 1998-01-09 2003-10-30 Flament-Garcia Mary Jane Container for an inhalation anesthetic
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DE69912441T2 (de) 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
EP1018827B1 (en) 1999-01-08 2004-05-06 Sony International (Europe) GmbH Synchronisation structure for OFDM system
TW523409B (en) 2000-09-15 2003-03-11 Baxter Int Container for inhalation anesthetic
ATE365034T1 (de) * 2003-09-10 2007-07-15 Cristalia Prod Quimicos Farm Stabile pharmazeutische zusammensetzung einer fluorether-verbindung für die anästhesie, verfahren zur stabilisierung einer fluorether- verbindung, verwendung eines stabilisierungsmittels zum ausschluss des abbaus einer fluorether-verbindung
BR0303489A (pt) * 2003-09-10 2005-07-05 Cristalia Prod Quimicos Farm Composição farmacêutica estabilizada de composto flúor-éter e método para inibir a degradação de composto flúor-éter. uso de agente estabilizante para inibir a degradação de composto flúor éter
US20060258755A1 (en) * 2005-04-18 2006-11-16 Terrell Ross C Preparation of sevoflurane with negligible water content
WO2009049460A1 (en) * 2007-10-15 2009-04-23 Jiangsu Hengrui Medicine Co., Ltd. New packaging material for sevoflurane
PL2244737T3 (pl) * 2008-01-22 2020-05-18 The Board Of Regents Of The University Of Texas System Kompozycje lotnego środka znieczulającego zawierające rozpuszczalniki ekstrakcyjne do znieczulania miejscowego i / albo zwalczania bólu
US20090275785A1 (en) 2008-05-01 2009-11-05 Barry Jones Distillation Method For The Purification Of Sevoflurane And The Maintenance Of Certain Equipment That May Be Used In The Distillation Process
US8563115B2 (en) 2008-08-12 2013-10-22 Xerox Corporation Protective coatings for solid inkjet applications
US8092822B2 (en) * 2008-09-29 2012-01-10 Abbott Cardiovascular Systems Inc. Coatings including dexamethasone derivatives and analogs and olimus drugs
US8283643B2 (en) * 2008-11-24 2012-10-09 Cymer, Inc. Systems and methods for drive laser beam delivery in an EUV light source
US8191992B2 (en) * 2008-12-15 2012-06-05 Xerox Corporation Protective coatings for solid inkjet applications
US9278048B2 (en) * 2009-05-06 2016-03-08 Baxter International, Inc. Pharmaceutical product and method of use
US9102604B1 (en) 2010-02-15 2015-08-11 Baxter International Inc. Methods for cleaning distilling columns
CN105193774B (zh) * 2015-09-21 2018-01-16 山东新时代药业有限公司 一种七氟烷吸入剂
CN105106182B (zh) * 2015-09-21 2017-12-29 山东新时代药业有限公司 七氟烷吸入剂
CA2952552C (en) 2016-11-02 2018-05-15 Central Glass Company, Limited Method for washing sevoflurane storage container and method for storing sevoflurane

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2992276A (en) * 1959-05-20 1961-07-11 Du Pont Process for preparing polyfluoro alkyl compounds
US3527813A (en) * 1966-10-03 1970-09-08 Air Reduction 1,1,2 - trifluoro - 2 - chloroethyl difluoromethyl ether and its method of preparation
US3689571A (en) * 1970-07-31 1972-09-05 Baxter Laboratories Inc Fluorinated ether
GB1499818A (en) * 1974-12-06 1978-02-01 Ici Ltd Anaesthetic composition
US4469898A (en) * 1979-12-26 1984-09-04 Baxter Travenol Laboratories, Inc. Method of synthesizing fluoromethylhexafluoroisopropyl ether
US4250334A (en) * 1979-12-26 1981-02-10 Baxter Travenol Laboratories, Inc. Method of synthesizing fluoromethylhexafluoroisopropyl ether
JP2786108B2 (ja) * 1994-03-31 1998-08-13 セントラル硝子株式会社 フルオロメチル−１，１，１，３，３，３−ヘキサフルオロイソプロピルエーテルの精製方法
IT1270239B (it) * 1994-06-17 1997-04-29 Zambon Spa Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo
US5990176A (en) * 1997-01-27 1999-11-23 Abbott Laboratories Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid

Also Published As

Publication number Publication date
EP0967975A1 (en) 2000-01-05
JP2005279283A (ja) 2005-10-13
CA2278133A1 (en) 1998-07-30
NO993606L (no) 1999-09-24
JP3664648B2 (ja) 2005-06-29
JP3183520B2 (ja) 2001-07-09
DE69833884T2 (de) 2006-08-24
US20040048932A1 (en) 2004-03-11
ES2256104T3 (es) 2006-07-16
CA2278133C (en) 2001-06-26
IL130150A (en) 2004-09-27
CN1152674C (zh) 2004-06-09
BG103656A (en) 2000-04-28
CN1899271A (zh) 2007-01-24
NO993606D0 (no) 1999-07-23
HUP0002101A3 (en) 2002-03-28
CO4920220A1 (es) 2000-05-29
CZ256199A3 (cs) 1999-11-17
AU5930098A (en) 1998-08-18
EP1114641A2 (en) 2001-07-11
BG65414B1 (bg) 2008-07-31
ATE320798T1 (de) 2006-04-15
DE69833884D1 (de) 2006-05-11
JP2000510159A (ja) 2000-08-08
IL130150A0 (en) 2001-03-19
TR199901579T2 (xx) 1999-12-21
EP1114641A3 (en) 2003-05-28
JP2001187729A (ja) 2001-07-10
PT1114641E (pt) 2006-05-31
DE69800928D1 (de) 2001-07-19
AR011090A1 (es) 2000-08-02
CA2626424A1 (en) 1998-07-30
ES2170474T3 (es) 2002-08-01
US6444859B2 (en) 2002-09-03
US6677492B2 (en) 2004-01-13
US6288127B1 (en) 2001-09-11
PT967975E (pt) 2001-11-30
PL334477A1 (en) 2000-02-28
HK1074434A1 (en) 2005-11-11
CN1244797A (zh) 2000-02-16
DK0967975T3 (da) 2001-09-17
US20060148906A1 (en) 2006-07-06
JP2006137769A (ja) 2006-06-01
GR3036190T3 (en) 2001-10-31
CN1560003A (zh) 2005-01-05
JP2006143742A (ja) 2006-06-08
US20030130359A1 (en) 2003-07-10
US20020016373A1 (en) 2002-02-07
DE69800928T2 (de) 2001-11-22
KR100368672B1 (ko) 2003-01-24
DK1114641T3 (da) 2006-05-15
BG109751A (bg) 2008-06-30
HUP0002101A2 (hu) 2001-05-28
SK284243B6 (sk) 2004-12-01
BR9806996A (pt) 2000-03-14
WO1998032430A1 (en) 1998-07-30
SK86199A3 (en) 2000-06-12
CZ297092B6 (cs) 2006-09-13
ATE201987T1 (de) 2001-06-15
AU726733B2 (en) 2000-11-16
US5990176A (en) 1999-11-23
EP1114641B1 (en) 2006-03-22
ZA98418B (en) 1999-04-20
CN1321958C (zh) 2007-06-20
KR20000070482A (ko) 2000-11-25
AR057610A2 (es) 2007-12-05
EP0967975B1 (en) 2001-06-13

Similar Documents

Publication Publication Date Title
NZ335994A (en) Sevoflurane compositions and methods for inhibiting their degradation in the presence of a lewis acid
HUP0103464A3 (en) Prodrugs of proton pump inhibitors and pharmaceutical compositions containing them
IL125223A0 (en) Novel substituted imidazole compounds
PL327934A1 (en) Novel substituted imidazole compounds
AU2059297A (en) Composition and dosage form comprising opioid antagonist
ZA973022B (en) New pharmaceutical composition with anaesthetic effect.
IL113812A (en) Copolymer-1 pharmaceutical compositions containing it and its use
GB2365772A (en) Factor
HUP0102281A3 (en) Prodrugs of dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
IL140338A0 (en) Amino acid derivatives which inhibit dipeptidyl peptidase iv and pharmaceutical compositions containing the same
HUP0104574A3 (en) Analogues of glp-1, pharmaceutical compositions comprising thereof and their use
TR199801679T2 (xx) Osteoporoz i�in birle�tirme terapisi.
EP0637450A3 (en) Method and composition for resuscitation of hereditary tissue.
PL319784A1 (en) Keratinocytic growth factor analoques
AP1424A (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
AU4298596A (en) Protracted glp-1 compositions
MY129572A (en) Pharmaceutical preparation containing a cyclopeptide and a chemotherapeutic agent or an angiogenesis inhibitor
AU4905097A (en) Thrombin inhibitors
ZA943177B (en) Topical anesthetic compositions
HUP0002117A3 (en) Clear, injectable formulation of an anesthetic compound
HUT74746A (en) Pharmaceutical compositions containing p antagonist
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
IL129957A (en) Substituted phenols and phenyl esters and pharmaceutical compositions containing them
BG104119A (en) A new composition

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired